Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 6, Issue SUPPLEMENT 1, 2008, Pages

  Sonpavde, Guru ^a   Hutson, Thomas E ^b  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mammalian target of rapamycin inhibitors; Monoclonal antibodies; Tyrosine kinase inhibitors

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AFLIBERCEPT; ALPHA INTERFERON; AMG 102; AMG 386; ANGIOGENESIS INHIBITOR; ARQ 197; AVI 951; AXITINIB; BAY 734506; BEVACIZUMAB; CEDIRANIB; DOCETAXEL; ENZASTAURIN; EVEROLIMUS; GSK 089; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MOTESANIB; PAZOPANIB; PERIFOSINE; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VOLOCIXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; AUTOIMMUNE THYROIDITIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAIR COLOR; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; INSOMNIA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID FUNCTION TEST; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; VOMITING;

EID: 70349329441     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.s.005     Document Type: Article

References (76)

1. (Pubitemid 46089672) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
2. Figlin R, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):256s (Abstract 5024).
3. (Pubitemid 46849157) Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
4. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
5. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
6. (Pubitemid 30117639) Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(suppl 1):S55-7.
7. (Pubitemid 350296300) Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
8. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at: the American Society of Clinical Oncology: the 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. Abstract 350.
9. (Pubitemid 46089673) Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
10. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007;25(18 suppl):240s (Abstract 5023).
11. (Pubitemid 46630489) Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
12. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
13. (Pubitemid 36910021) Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
14. (Pubitemid 41103603) Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
15. (Pubitemid 350216728) Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6.
16. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007;25(18 suppl):244s (Abstract 5038).
17. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(18 suppl):261s (Abstract 5106).
18. George DJ, Michaelson MD, Rosenberg JE, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) : updated results and analysis of circulating biomarkers. J Clin Oncol 2007; 25:5035.
19. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26(15 suppl):280s (Abstract 5123).
20. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
21. (Pubitemid 43927103) Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
22. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
23. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26(15 suppl):261s (Abstract 5046).
24. (Pubitemid 47629888) Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: 975-84.
25. Dutcher JP, Wilding G, Hudes GR, et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008;26(15 suppl):281s (Abstract 5127).
26. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 2008;26(15 suppl):261s (Abstract 5047).
27. (Pubitemid 47548567) Heymach J V, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-7.
28. (Pubitemid 47548568) Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-84.
29. Aveo Pharmaceuticals website. Available at: http://www.aveopharma.com. Accessed: December 10, 2008.
30. Eskens FA, De Jonge MJ, Esteves B et al. Updated results from a phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. Presented at: the 99th Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract LB-201.
31. Aveo Pharmaceuticals [press release]. Available at: http://www. aveopharma.com/content/index.jsp. Accessed: December 10, 2008.
32. Stavropoulos JA, Meulbroek JA, Niquette AL, et al. Preclinical Activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with Paclitaxel. J Clin Oncol 2005;23(16 suppl):235s (Abstract 3175).
33. Zhou J, Pan M, Loh S, et al. ABT-869, a novel multi-target receptor tyrosine kinase inhibitor (RTKI), combined with chemotherapy is synergistic in the therapy of acute myeloid leukemia cells with FLT3-ITD mutation (FLT3-AML). J Clin Oncol 2006;24(18 suppl):607s (Abstract 13064).
34. Soo RA, McKeegan E, Chen CS, et al. The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome. J Clin Oncol 2008;26(15 suppl):630s (Abstract 14535).
35. Eder JP, Appleman L, Heath E, et al. A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J Clin Oncol 2006;24(18 suppl):131s (Abstract 3041).
36. Eder JP, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007;25(18 suppl):144s (Abstract 3526).
37. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 2008;26(15 suppl):275s (Abstract 5103).
38. Frost A, Buechert M, Unger C, et al. Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: final results of a dose-escalation study. J Clin Oncol 2008;26(15 suppl):126s (Abstract 2558).
39. (Pubitemid 33104280) Yu Y, Varughese J, Brown LF et al. Increased Tie-2 expression, enhanced response to angiopoietin-1 and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001;159:2271-80.
40. Gale N, Thurston G, Hackett S, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Cell 2002;3:411-23.
41. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002;198:502-10.
42. AMG 386 Investigator Brochure.
43. Rosen LS, Hong D, Chap L, et al. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. J Clin Oncol 2007;25(18 suppl):143s (Abstract 3522).
44. Mita AC, Wang D, Takimoto CH, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. J Clin Oncol 2007;25(18 supp) : (Abstract 14033).
45. Yazji S, Bukowski R, Kondagunta GV, et al. Final results from phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). J Clin Oncol 2007;25(18 suppl):477s (Abstract 5094).
46. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2005;23(16 suppl):199s (Abstract 3029).
47. Camidge DR, Eckhardt SG, Diab S, et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol 2006;24(18 suppl):140s (Abstract 3032).
48. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs 2008;17:939-44.
49. (Pubitemid 44845615) Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006;107:2609-16.
50. Amato RJ, Hernandez-McClain J, Saxena S, et al. Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 2008;31:244-9.
51. Whorf RC, Hainsworth J, Spigel DR, et al. Phase II study of bevacizumab and everolimus in the treatment of advanced renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):252s (Abstract 5010).
52. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95.
53. Ryan CW, Goldman BH, Lara PN, Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25:3296-301.
54. Tannir NM, Zurita AJ, Heymach JV, et al: A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alpha: Clinical results and biomarker analysis. J Clin Oncol 2008;26(15 suppl):272s (Abstract 5093).
55. February 14-16 Bracarda S, Porta C, Boni C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY) : GOIRC Study 0681. Presented at: the American Society of Clinical Oncology: the 2008 Genitourinary Cancer Symposium; February 14-16, 2008; San Francisco, CA. Abstract 357.
56. Sosman J, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib with bevacizumab in metastatic renal cell cancer patients. J Clin Oncol 2008;26(15 suppl):252s (Abstract 5011).
57. Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):672s (Abstract 16020).
58. Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):274s (Abstract 5100).
59. Cooney MM, Garcia JA, Elson P, et al. Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. J Clin Oncol 2008;26(15 suppl):160s (Abstract 3530).
60. Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol 2007;25(18 suppl) : (Abstract 15622).
61. Schreeder MT, Figlin RA, Stephenson JJ, et al. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. J Clin Oncol 2008;26(15 suppl):673s (Abstract 16024).
62. Yap TA, Harris D, Barriuso J, et al. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J Clin Oncol 2008;26(15 suppl):173s (Abstract 3584).
63. Reardon DA, Cloughsey T F, Raizer JJ, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol 2008;26(15 suppl):101s (Abstract 2051).
64. Rosen PJ, Sweeney CJ, Park DJ, et al. AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J Clin Oncol 2008;26(15 suppl):170s (Abstract 3570).
65. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofet al. antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-7.
66. Harrop R, McDermott C, Shablak A, et al. Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNα: A phase II trial. J Clin Oncol 2008;25(15 suppl):145s (Abstract 3053).
67. Hernandez-McClain J, Amato RJ, Shingler WH, et al. Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax [T]) administered + low dose interleukin-2 (IL-2) : a phase II trial. J Clin Oncol 2008;26(15 suppl):274s (Abstract 5101).
68. Yang JC, Beck KE, Blansfield JA, et al. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol 2005;23(16 suppl):166s (Abstract 2501).
69. Huang H, Menefee ME, Edgerly M, et al. Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(15 suppl):262s (Abstract 5053).
70. (Pubitemid 34032623) Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
71. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41.
72. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543-50.
73. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 2007;25(18 suppl):240s (Abstract 5023).
74. Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008;26(15 suppl):252s (Abstract 5008).
75. Choueiri TK, Vaziri SA, Rini BI, et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol 2007; 25:5012.
76. (Pubitemid 47584475) Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379-85.